Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$10.0 million","newsHeadline":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellvera

    Menu

    Cellvera

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cellvera

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avig...

              Details:

              Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Aditxt

              Deal Size: $10.0 million Upfront Cash: $10.0 million

              Deal Type: Agreement April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellvera

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th

              Details:

              Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious diseases including Avigan.

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Aditxt

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY